drugset / Trial / NCT00276029

TNF Alpha in Refractory Asthma

NCT00276029

Completed 10 enrolled University Hospitals, Leicester
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study was to investigate whether the administration of etanercept to patients with severe asthma improved their asthma related quality of life and a measure of the degree of reactivity of the airways

Timeline

Start
2003-12
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg

Indications